Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.
Malignant Neoplasm of Breast|CNS Malignancy|Malignant Neoplasm of Gastrointestinal Tract|Genitourinary Neoplasms Malignancy and Gender Unspecified|Head and Neck Neoplasms|Melanoma|Malignant Neoplasm of Thorax
DRUG: Alisertib|DRUG: Pazopanib
Optimally Tolerated Dose, Complete all planned treatment for cycle 1 (defined as 14 doses of alisertib and daily pazopanib) without dose limiting toxicity and are able to start cycle 2 with no more than a 2 week delay., At end of Cycle 1 (approximately Day 21)
Toxicity Profile, Adverse events which occur after taking at least one dose of study treatment with either alisertib and/or pazopanib., Within 30 days of Last Treatment Dose
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.